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Abstract. Poly(ADP-ribose) polymerase (PARP)-1 is a 
pro‑inflammatory protein. The inhibition of PARP‑1 reduces 
the activity of numerous pro‑inflammatory transcription 
factors, which results in the reduced production of pro‑inflam-
matory cytokines, chemokines, matrix metalloproteinases and 
inducible nitric oxide synthase, culminating in reduced inflam-
mation of the skin and other organs. The aim of the present 
study was to investigate the effects of the deletion of PARP‑1 
expression on polyunsaturated fatty acids (PUFA), and PUFA 
metabolite composition, in mice under control conditions or 
undergoing an oxazolone (OXA)‑induced contact hypersen-
sitivity reaction (CHS). CHS was elicited using OXA in both 
the PARP‑1+/+ and PARP‑1�/� mice, and the concentration 
of PUFAs and PUFA metabolites in the diseased skin were 
assessed using lipidomics experiments. The levels of docosa-
hexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were 
shown to be increased in the PARP‑1�/� mice, as compared with 
the control, unsensitized PARP‑1+/+ mice. In addition, higher 
expression levels of fatty acid binding protein 7 (FABP7) were 
detected in the PARP‑1�/� mice. FABP7 is considered to be 
a specific carrier of DHA and EPA. Furthermore, the levels 
of the metabolites of DHA and EPA (considered mainly as 
anti‑inflammatory or pro‑resolving factors) were higher, as 
compared with the metabolites of arachidonic acid (consid-
ered mainly pro‑inflammatory), both in the unsensitized 
control and OXA‑sensitized PARP‑1�/� mice. The results of 
the present study suggest that the genetic deletion of PARP‑1 
may affect the PUFA‑homeostasis of the skin, resulting in 
an anti‑inflammatory milieu, including increased DHA and 
EPA levels, and DHA and EPA metabolite levels. This may 
be an important component of the anti‑inflammatory action of 
PARP‑1 inhibition.
Introduction
Poly(ADP‑ribose) polymerases (PARPs) comprise a super-
family containing 17 members in humans (1). Numerous 
PARP-1, -2, -14 and tankyrases have previously been shown to 
mediate inflammatory reactions (2‑6), and PARP‑1 has been 
associated with inflammatory or oxidative stress‑related skin 
pathologies (7‑9). PARP‑1 is an important pro‑inflammatory 
mediator with important roles in the maturation of immune 
cells (10‑12), activation of pattern recognition receptors (13‑19), 
activation of pro‑inflammatory transcription factors (6), and 
reactive species (20).
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The contact hypersensitivity (CHS) reaction is a T‑cell medi-
ated, delayed type hypersensitivity reaction that is elicited by low 
molecular weight molecules, such as oxazolone (OXA) (21,22). 
Upon sensitization, infiltrating cells and keratinocytes produce 
free radicals, pro‑inflammatory cytokines, adhesion molecules 
and matrix metalloproteinases in a PARP‑1 and nuclear 
factor‑κB‑dependent manner, resulting in the induction of 
inflammation (6,7,20,23‑25). PARP‑1 expression inhibition, or 
knock‑out, has been shown to reduce the severity of experi-
mental CHS (7,26). The present study aimed to characterize 
whether alterations of eicosanoid and docosanoid metabolism 
and signaling may contribute to the anti‑inflammatory effects of 
PARP‑1 expression ablation.
Materials and methods
Materials. OXA and the other chemicals used in the present 
study were obtained from Sigma‑Aldrich (St. Louis, MO, USA), 
unless stated otherwise.
Animal experiments. All of the experiments performed 
on mice were approved by the Local Ethical Committee 
(9/2008/DE MÁB) and were performed according to EU and 
national guidelines. PARP-1+/+ and PARP‑1-/- mice, derived from 
heterozygote‑to‑heterozygote breeding, were kept in the animal 
facility of the Life Science Building, University of Debrecen 
(Debrecen, Hungary) (27). A CHS model was constructed 
as described by previous methods (7). Briefly, the mice were 
randomized into four groups: PARP‑1+/+ vehicle sensitized 
(control), PARP‑1�/� vehicle sensitized (control), PARP‑1+/+ OXA 
sensitized (CHS) and PARP‑1�/� OXA sensitized (CHS) groups 
(n=5/5/6/5). Sensitization was carried out on the shaved abdom-
inal wall skin of the mice, with an administration of 100 µl 2% 
OXA solubilised in acetone : olive oil (4:1; CHS groups), or 
100 µl vehicle of acetone:olive oil (4:1; control groups). Seven 
days after sensitization, all of the mice were challenged with 
100 µl 0.5% OXA, which was applied to the epidermis of the 
shaved back. After 24 h, the mice were sacrificed and the skin 
was harvested.
Histology and microscopy. Hematoxylin‑eosin staining and 
immunohistochemistry was performed on paraffin‑fixed 7 µm 
tissue sections, as described previously (7).
High performance liquid chromatography‑electrospray 
tandem mass spectrometry (HPLC‑ESI‑MS‑MS) analysis. The 
procedure for the HPLC‑ESI‑MS‑MS analysis The analysis of 
free fatty acids, eicosanoids and docosanoids in the skin was 
performed, according to previously described methods (28), 
with minor modifications.
Sample preparation. The whole analytical sample prepara-
tion procedure used was based on an established method used 
for retinoid quantification (29). Briefly, 50 mg skin biopsy, was 
treated with 150 µl acetonitrile and the skin samples were cut 
into small pieces with scissors, on ice. If less than 50 mg of 
skin biopsy was present, water was added to yield 50 mg of 
sample weight. The mixtures were agitated for 3 min, and the 
precipitated protein was centrifuged at 16060 g (13,000 rpm), 
4˚C for 6 min. A total of 130 µl resulting supernatant was 
mixed with 10 µl isotope supernatant mix and evaporated in 
Eppendorf reaction vials (Eppendorf, Hamburg, Germany) 
using an Eppendorf concentrator at 30˚C for ~60 min, until 
the sample volume was ~10 µl. The Eppendorf concentrator 
was vented with argon, in order to prevent degradation of 
eicosanoids and docosanoids. The dried extract was resus-
pended in ~25 µl HPLC solvent A [64.3% water (Chromasolv 
Plus; Sigma‑Aldrich, Budapest, Hungary), 35.5% acetonitrile 
(Merck KGaA, Darmstadt, Germany) and 0.2% formic acid 
(Sigma‑Aldrich, Hungary)] to yield 35 µl. The sample was then 
vortexed (15 sec), agitated (3 min) and transferred into micro 
injection inserts vials (Waters, Budapest, Hungary). The glass 
vials containing 35 µl extract were transferred into brown 
screw top vials with PTFE/silicone septa (Waters), and placed 
into the pre‑cooled (15˚C) autosampler of the Waters 2695XE 
separation module.
Chromatographic system. The HPLC system consisted 
of a Waters 2695XE separation module (Waters) including 
a gradient pump, autosampler, degasser and a heated column 
compartment. A MS‑MS detector, with an ESI ionizing option, 
(Micromass Quattro Ultima PT; Waters, Elstree, UK; a gift 
from Biosystems Int., France) was used as the detector. The 
system was controlled using MassLynx software (Waters).
HPLC conditions. The eluents were degassed in the 
Waters 2695XE separation module prior to mixing, and passed 
through an in‑line filter (1‑2 µm; Knauer, Berlin, Germany) 
before reaching the analytical column (LiChroCART, 
125x2 mm; Superspher 100, RP‑18, endcapped; Merck KgaA), 
which was embedded in the column compartment. A multilinear 
gradient was formed from solvent A (as mentioned previously) 
and solvent B (methanol; Merck KGaA). The gradient consisted 
of the following steps: 0.0 min 20% B, 3.0 min 20% B, 5.0 min 
60% B, 15.0 min 100% B, 15.9 min 100% B and 16.0 min 5% 
B. The flow rate was adjusted to 0.4 ml/min and the column was 
heated to 40˚C. From the same biological extract, 10 µl was used 
for each HPLC analysis. This step was performed twice, using 
the same HPLC conditions, and two different MS‑MS analysis 
options were conducted for better resolution and quantification 
of the various analytes.
MS options. The Micromass Quattro Ultima PT was 
controlled using MassLynx software. Argon was used with an 
inlet pressure of 0.8 bar. ESI (electro spray ionization source; 
Waters) was vented by nitrogen, which was continuously 
produced by a nitrogen generator (Peak Scientific NM30 
Nitrogen generator; Peak Scientific, Billerica, MA, USA) 
including a compressor (Waters), the inlet flow was set at 
3.6x10‑3 mbar.
Multiple reaction monitoring settings. ESI, with a negative 
ESI‑setting, was performed with the HPLC eluent, following 
the ion source temperature of 85˚C. The desolvation gas flow 
was 780 l/h, the desolvation temperature was 400˚C, the 
cone gas flow was 10 l/h, the capillary current was 3 µA, 
and the cone voltage was 50 V. The aperture voltage was set 
at 0 V and the range‑finder lens voltage was set at 35 V (for 
one) and 0.2 V (for two). The analyzer settings were LM1 
resolution, 14.5; HM1 resolution, 14.5; ion energy, 10.7; 
entrance, -1; collision, 0 (collision parameters were set for 
each substance at the MS‑method parameters); exit, 2; LM2 
resolution, 14.5; HM2 resolution, 14.5; ion energy, 25.0 and 
multiplier energy, 650 V.
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Multiple reaction monitoring settings for polyunsaturated fatty 
acids (PUFA), eicosanoids/docosanoids semi‑quantification. 
The following methods were used, as described in a previous 
study (27): Method A from 0.0-9.0 min for PGF2 349.0 ‑> 192.7, 
collision energy 22 eV; PD1 and PD1 isomers, like PDX, 359.0 
‑> 153.3, collision energy 17 eV; TXB2 369.0 ‑> 195.0, collision 
energy 13 eV; PGE3 349.0 ‑> 233.0, collision energy 17 eV; 
LXA4 / LXB4 351.0 ‑> 115.0, collision energy 12 eV; 8iPGF3 
351.0 ‑> 193.0, collision energy 22 eV; 20‑COOH‑LTB4 
365.0 ‑> 195.0, collision energy 13 eV; RvD1, RvD2 375.0 ‑> 
141.3, collision energy 13 eV; RvE1 375.1 ‑> 141.3, collision 
energy 13 eV. From 9.0‑12.5 min for 13‑HODE 294.7 ‑> 170.7, 
collision energy 16 eV; 9‑HODE 294.7 ‑> 194.7, collision 
energy 16 eV; 5‑HEPE 317.0 ‑> 115.0, collision energy 17 eV; 
12‑HEPE 317.0 ‑> 179.0, collision energy 17 eV; 15‑HEPE 
317.0 ‑> 219.0, collision energy 17 eV, LTC4 623.9 ‑> 272.0, 
collision energy 14 eV. From 12.5‑16.0 min for LA 279.3 
‑> 279.0, collision energy 10 eV; 8‑HEPE 317.0 ‑> 255.0, 
collision energy 17 eV; 18‑HEPE 317.0 ‑> 259.0, collision 
energy 17 eV; 5‑oxoETE, 12‑oxoETE and 15‑oxoETE 317.0 
‑> 273.0, collision energy 17 eV; 20‑HETE 319.0 ‑> 245.0, 
collision energy 10 eV; LTC4 623.9 ‑> 272.0, collision energy 
14 eV; LTE4 438.0 ‑> 333.0, collision energy 13 eV. From 
12.5‑16.0 min for LA 279.3 ‑> 59.2, collision energy 25 eV; 
EPA 301.0 ‑> 203.2, collision energy 12 eV; AA 303.0 ‑> 259.3, 
collision energy 14 eV; DHA 327.1 ‑> 29.3, collision energy 
14 eV.
Method B (27) from 0.0‑9.8 min for PGE2, d15d12PGD2, 
PGD2, d15d12PGJ2 and PGJ2 315.0 ‑> 271.3, collision energy 
13 eV; LTB5 333.0 ‑> 195.0, collision energy 13 eV; LTB4 335.0 
‑> 195.0, collision energy 13 eV; RvE1 349.1 ‑> 195.3, collision 
energy 13 eV; HXA3, HXB3 and 20‑COOH‑AA 335.0 ‑> 273.3, 
collision energy 13 eV; LXA5 349.0 ‑> 115.0, collision energy 
12 eV; 20‑OH‑LTB4 351.0 ‑> 195.0, collision energy 13 eV; 
MaR 359.0 ‑> 250.0, collision energy 13 eV. From 9.8‑12.5 min 
for 5‑HETE 318.7 ‑> 115.0, collision energy 14 eV; 8‑HETE 
319.0 ‑> 155.0, collision energy 14 eV; 11‑HETE 319.0 ‑> 167.0, 
collision energy 14 eV; 12‑HETE 319.0 ‑> 179.0, collision 
energy 14 eV; 15‑HETE 319.0 ‑> 218.9, collision energy 11 eV; 
4‑HDHA 343.0 ‑> 101.0, collision energy 10 eV; 10‑HDHA 
343.0 ‑> 181.0, collision energy 10 eV; 14‑HDHA 343.0 ‑> 
205.0, collision energy 10 eV; 17‑HDHA 343.0 ‑> 245.0, colli-
sion energy 14 eV, 20‑HDHA 343.0 ‑> 285.0, collision energy 
10 eV; 13‑oxoODE 293.0 ‑> 249.0, collision energy 17 eV. And 
from 12.5‑16.0 min for LA 279.3 ‑> 59.2, collision energy 25 eV; 
EPA 301.0 ‑> 203.2, collision energy 12 eV; AA 303.0 ‑> 
259.3, collision energy 11 eV; and DHA 327.1 ‑> 229.3, colli-
sion energy 14 eV.
Standard solutions. Stock solutions of the PUFAs, eicosanoids 
and docosanoids were prepared by dissolving the solutions in 
methanol to yield a final concentration of 10 µg/ml. The solutions 
were obtained from Cayman‑Chemicals (Tallinn, Estonia), 
BioMol International (Kastel‑Med KFT, Budapest, Hungary), 
Sigma‑Aldrich (Hungary), Larodan Lipids (Malmö, Sweden) and 
Dr. Charles Serhan (Harvard, MA, USA). All stock solutions 
were stored in the dark, at -80˚C until further use. The reference 
PUFAs, eicosanoids and docosanoids (BioMol International/
Enzo Life Sciences, Farmingdale, NY, USA) were used for 
assay validation.
Quantification. Individual eicosanoids and docosanoids 
were quantified based on the determination of the area 
under the curve (AUC), which was compared with the AUC 
of the standard compounds. To ensure optimal extrac-
tion, isotope‑labelled standard compounds were used. This 
analytical procedure was previously established for liquids 
and tissue analysis (28).
Table I. Oligonucleotides used in quantitative polymerase chain reactions.
Gene Sequence
Mouse 36B4 5'‑AGA TTC GGG ATA TGC TGT TGG‑3'
 5'‑AAA GCC TGG AAG AAG GAG GTC‑3'
Mouse GAPDH 5'‑CAA GGT CAT CCA TGA CAA CTT TG‑3'
 5'‑GGC CAT CCA CAG TCT TCT GG‑3'
Mouse cyclophyllin 5'‑TGG AGA GCA CCA AGA CAG ACA‑3'
 5'‑TGC CGG AGT CGA CAA TGA T‑3'
Mouse FABP7 5'‑GAG TAC ATG AAA GCT CTG GGC‑3'
 5'‑AAC CGA ACC ACA GAC TTA CAGT T‑3'
Mouse COX2 5'‑GTG AAG GGA AAT AAG GAG CTT CC‑3'
 5'‑GTG ATT TAA GTC CAC TCC ATG GC‑3'
Human 36B4 5'‑CCA TTG AAA TCC TGA GTG ATG TG‑3'
 5'‑GTC GAA CAC CTG CTG GAT GAC‑3'
Human actin 5'‑GAC CCA GAT CAT GTT TGA GAC C‑3'
 5'‑CAT CAC GAT GCC AGT GGT AC‑3'
Human cyclophyllin 5'‑GTC TCC TTT GAG CTG TTT GCA GAC‑3'
 5'‑CTT GCC ACC AGT GCC ATT ATG‑3'
Human PARP‑1 5'‑CAC TGG TAC CAC TTC TCC TGC TTC‑3'
 5'‑CTT TGC CTG TCA CTC CTC CAG‑3'
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Figure 1. Deletion of poly(ADP‑ribose) polymerase‑1 (PARP‑1) suppresses neutrophil migration. Formalin‑fixed, paraffin‑embedded tissue sections were 
stained with (A) hematoxylin and eosin and (B) DAPI counterstain (blue) and an anti‑neutrophil elastase antibody (green) to detect neutrophil elastase. The 
arrows indicate the neutrophil elastase‑positive cells. The neutrophil elastase staining was observed to be cytoplasmic. Scale bars: A, 30 µm; B, 10 µm.
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mRNA preparation, reverse transcription and quantitative 
polymerase chain reaction (qPCR). Total RNA extraction, 
reverse transcription, and a subsequent qPCR, were performed 
as described previously (7). The primers used are listed in 
Table I.
Establishment of a PARP‑1 knockdown HEK293T cell line and 
luciferase reporter assays. HEK293T human embryonic kidney 
cells (American Type Culture Collection, Manassas, VA, USA) 
were maintained in Dulbecco's modified Eagle's medium, supple-
mented with 4.5 g/l glucose, 10% fetal calf serum, 2.5 µg/ml 
puromycin. These cells stable expressing a small hairpin (sh)
RNA specifically targeting PARP‑1 (pLKO.1‑PARP1). pLKO.1 
was used in the control cells (Sigma‑Aldrich, USA). PARP‑1 
expression was subsequently suppressed, as confirmed by qPCR.
pLightSwitch_PromFABP7 (Switchgear Genomics, 
Carlsbad, CA, USA) and pCMV‑βgal were transfected into 
the above cell line using jetPEI (PolyPlus Transfections SA, 
Illkirch, France). Following a 24 h incubation, the luciferase 
and β‑galactosidase activities were determined. Luciferase 
activity was normalized to β‑galactosidase activity.
Statistical analysis. The results of the cell assays are 
expressed as the means ± standard deviation, and statistical 
significance between the groups was determined by Student's 
t‑test. The results of the in vivo studies are expressed as the 
means, and statistical significance was determined using 
the Kruskal‑Wallis and Mann‑Whitney tests. A P<0.05 was 
considered to indicate a statistically significant difference.
Results
Neutrophil infiltration and edema at the site of the CHS reac-
tion was observed in the histological examinations; however, 
Figure 2. Eicosanoid and docosanoid signaling alterations in the skin of poly(ADP‑ribose) polymerase‑1 (PARP‑1)�/� mice, due to enhanced fatty acid binding 
protein (FABP)7 expression. The FABP7 mRNA expression levels, and eicosanoid and docosanoid concentrations, were determined in the skin of control 
(PARP-1+/+ NS), OXA‑sensitized PARP‑1+/+ (PARP-1+/+ SENS) and respective PARP‑1�/� mice (n=5/5/6/5). AA,  arachidonic acid; DHGLA, dihomo‑gamma‑
linoleic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; MET, metabolites; COX, cyclooxygenase; COX2, cyclooxygenase 2; Pg, prostaglandin.
Figure 3. Reduction in the expression levels of poly(ADP‑ribose) polymerase‑1 (PARP‑1) in response to specific small hairpin (sh)RNA treatment of HEK293T 
human embryonic kidney cells. PARP‑shRNA also induced the activity of the fatty acid binding protein (FABP)7 promoter. (A) PARP‑1 expression levels were 
reduced in HEK293T cells using a construct coding an shRNA against PARP‑1 (shPARP‑1), as determined by quantitative polymerase chain reaction (n=3/3). 
(B) Promoter activity of FABP7 was determined in luciferase reporter assays in control (scPARP‑1 HEK2935T) and shPARP‑1 HEK293T cells (n=3/3). 
*P<0.05, PARP‑1+/+ mice, compared with PARP‑1‑/‑ mice; ***P<0.001, scPARP‑1, compared with shPARP‑1 HEK293T cells.
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the levels of these were reduced in the PARP‑1�/� mice (Fig. 1A 
and B). This finding indicates that PARP‑1 may contribute 
to inflammation in CHS, therefore PARP‑1�/� mice may be 
protected against CHS. These results are concordant with our 
previous observations (7,26,30).
The qPCR detected higher mRNA expression levels of fatty 
acid binding protein (FABP)7 in the PARP‑1�/� mice (Fig. 2). 
The depletion of PARP‑1 expression (Fig. 3A) induced the 
activity of the FABP7 promoter (Fig. 3B), suggesting that 
PARP‑1 may have direct effects on the FABP7 promoter.
Using a lipidomic approach, the composition of eico-
sanoids and docosanoids in the skin was determined. There 
was an increase in four of the major PUFAs, which are 
precursors of eicosanoids and docosanoids: Arachidonic 
acid (AA; 20:4 n‑6), dihomo‑gamma‑linoleic acid (DHGLA; 
20:3 n‑6), docosahexaenoic acid (DHA; 22:5 n‑3) and eicosa-
pentaenoic acid (EPA; 20:5 n‑3). These free fatty acids had 
increased levels in the skin of the control and OXA‑challenged 
PARP-1�/� mice, as compared with their respective PARP‑1+/+ 
cohorts (Fig. 2).
The levels of AA‑metabolites (AA MET), as compared 
with the mother compound AA (AA MET/AA), as well as 
EPA MET/EPA and DHA MET/DHA, had lower ratios in 
the non‑sensitized animals, and the n3‑PUFAs ratios were 
increased in the sensitized animals (Fig. 2). The sum of the 
cyclooxygenase (COX) metabolites (COX SUM), and the levels 
of COX metabolites prostaglandin E2 (PgE2) and PgD2, as 
well as the PgE2/AA and PgD2/AA ratios, were all decreased 
showing reduced synthesis of pro‑inflammatory lipid media-
tors. The levels of anti‑inflammatory or pro‑resolving n3‑PUFA 
metabolites were mainly increased, resulting from EPA and 
DHA‑metabolism (31) in the PARP‑1�/� animals (Fig. 2). These 
data are concordant with the decreased expression levels of 
COX‑2 in the PARP‑1-/- mice(Fig. 2).
Discussion
In the present study, it was determined that ablation of PARP‑1 
expression had characteristic effects on skin eicosanoid and 
docosanoid signaling, and metabolism. The two n‑3 PUFAs 
(DHA and EPA), DHA‑ and EPA‑metabolites, and the ratios 
of DHA‑ and EPA‑metabolites vs. AA‑metabolites were 
increased, indicating a pro‑resolving, anti‑inflammatory 
environment (31) in the PARP‑1�/� mice, especially following 
OXA‑sensitization. The formation of the pro‑inflammatory 
COX‑metabolites was lower in the skin of the PARP‑1�/� mice, 
which is concordant with a previously determined anti‑inflam-
matory environment (6). PARP‑1 has previously been shown 
to regulate COX‑2 expression (32) which may explain the 
observed decrease in COX‑2 metabolites.
It may be suggested that increased FABP7‑levels are 
responsible for the observed alterations of lipid mediator 
signaling. FABP7 has preference towards n‑3, as compared 
with n‑6, PUFAs (33), this may be a plausible explanation for 
the accumulation of EPA‑derived metabolites, and increased 
ratios of PUFA‑metabolites (DHA/AA MET, EPA/AA MET) 
in the PARP‑1+/+ mice.
The results of the present study widen the spectrum of 
altered lipid metabolism upon PARP‑1 expression abla-
tion (34,35), by implicating skin eicosanoid and docosanoid 
metabolism and signaling. A reduction in PARP‑1 expres-
sion results in a reduced pro‑inflammatory and increased 
pro‑resolving or anti‑inflammatory environment in the skin. 
Higher levels of the DHA and EPA metabolites, and reduced 
COX‑pathway metabolites were previously implicated in 
a reduction of DNFB‑induced CHS (36), peritonitis (31), 
atopy (37) or allergy (38).
These data are concordant with our previous findings, 
which showed that genetic or pharmacological inhibition 
of PARP‑1 is capable of protecting against CHS (7,26,39). 
Notably, differences in eicosanoid and docosanoid metabo-
lism and signaling are also present in unchallenged mice and 
it may be speculated that these minor changes may render 
PARP-1�/� mice less susceptible to CHS. Furthermore, the 
changes to gene expression levels and lipid mediator compo-
sition are associated with inflammatory pathologies that are 
mediated not only by T‑helper (Th) 1 or Th2 cells, but also 
the newly defined Th17 cells, which have previously been 
associated with the induction of FABPs in psoriasis (40). 
In conclusion, alteration in skin eicosanoid and docosanoid 
metabolism and signaling may modify the barrier function 
of the skin, wherein the role of PARPs remains relatively 
unexplored.
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